EXPLORING THE CONCEPT OF HUMAN OCT3 INHIBITORS AS A NOVEL CLASS OF ANTIDEPRESSANTS

The Dukat laboratory developed 2-amino-6-chloro-3,4-dihydroquinazoline (A6CDQ) as a 5-HT3 receptor ligand. A6CDQ and one of its positional isomers, the 7-chloro analog A7CDQ, produced antidepressant-like effects in the mouse tail suspension test (TST). We investigated and systematically ruled out a...

Full description

Bibliographic Details
Main Author: Iyer, Kavita A
Format: Others
Published: VCU Scholars Compass 2016
Subjects:
SAR
Online Access:http://scholarscompass.vcu.edu/etd/4607
http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=5674&context=etd
id ndltd-vcu.edu-oai-scholarscompass.vcu.edu-etd-5674
record_format oai_dc
spelling ndltd-vcu.edu-oai-scholarscompass.vcu.edu-etd-56742017-03-17T08:35:25Z EXPLORING THE CONCEPT OF HUMAN OCT3 INHIBITORS AS A NOVEL CLASS OF ANTIDEPRESSANTS Iyer, Kavita A The Dukat laboratory developed 2-amino-6-chloro-3,4-dihydroquinazoline (A6CDQ) as a 5-HT3 receptor ligand. A6CDQ and one of its positional isomers, the 7-chloro analog A7CDQ, produced antidepressant-like effects in the mouse tail suspension test (TST). We investigated and systematically ruled out a solely 5-HT3 receptor or hSERT mediated mechanism of antidepressant-like effect for both A6CDQ and A7CDQ. The role of organic cation transporter 3 (OCT3) as an alternative mechanism in the regulation of neurotransmitters including serotonin (5-HT) and the therapeutic potential of targeting hOCT3 to achieve antidepressant effects has been established. By virtue of possessing protonatable nitrogen atoms, 2-aminodihyroquinazolines could potentially exhibit activity at OCT3. A major goal of our present study was to explore the non-serotonergic mechanism of antidepressant-like effects and to study the as yet unexplored structure-activity-relationships (SARs) at OCT3. We examined the role of i) the chloro group, ii) the methylene bridge and iii) electronic/lipophilic effects at the 6-position. We developed the first 3-D homology models of both the human and mouse orthologs of OCT3, conducted docking studies and HINT analysis, and identified critical amino acid residues interacting with 2-aminodihydroquinazoline analogs at hOCT3 and mOCT3. Retention of antidepressant-like activity in the mouse and potential locomotor stimulant effects for TST-active doses were thoroughly investigated. We have successfully investigated initial SAR of 2-aminodihydroquinazolines at hOCT3 and generated the first 3-D homology models of hOCT3 and mOCT3. Highly potent and selective compounds could potentially be developed as radioligands to probe the binding site of OCT3 and as a mechanistically novel class of antidepressants. 2016-01-01T08:00:00Z text application/pdf http://scholarscompass.vcu.edu/etd/4607 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=5674&context=etd © The Author Theses and Dissertations VCU Scholars Compass OCT3 homology modeling SAR depression quinazoline tail suspension test HINT QSAR hSERT 5-HT3 receptors Medicinal and Pharmaceutical Chemistry
collection NDLTD
format Others
sources NDLTD
topic OCT3
homology modeling
SAR
depression
quinazoline
tail suspension test
HINT
QSAR
hSERT
5-HT3 receptors
Medicinal and Pharmaceutical Chemistry
spellingShingle OCT3
homology modeling
SAR
depression
quinazoline
tail suspension test
HINT
QSAR
hSERT
5-HT3 receptors
Medicinal and Pharmaceutical Chemistry
Iyer, Kavita A
EXPLORING THE CONCEPT OF HUMAN OCT3 INHIBITORS AS A NOVEL CLASS OF ANTIDEPRESSANTS
description The Dukat laboratory developed 2-amino-6-chloro-3,4-dihydroquinazoline (A6CDQ) as a 5-HT3 receptor ligand. A6CDQ and one of its positional isomers, the 7-chloro analog A7CDQ, produced antidepressant-like effects in the mouse tail suspension test (TST). We investigated and systematically ruled out a solely 5-HT3 receptor or hSERT mediated mechanism of antidepressant-like effect for both A6CDQ and A7CDQ. The role of organic cation transporter 3 (OCT3) as an alternative mechanism in the regulation of neurotransmitters including serotonin (5-HT) and the therapeutic potential of targeting hOCT3 to achieve antidepressant effects has been established. By virtue of possessing protonatable nitrogen atoms, 2-aminodihyroquinazolines could potentially exhibit activity at OCT3. A major goal of our present study was to explore the non-serotonergic mechanism of antidepressant-like effects and to study the as yet unexplored structure-activity-relationships (SARs) at OCT3. We examined the role of i) the chloro group, ii) the methylene bridge and iii) electronic/lipophilic effects at the 6-position. We developed the first 3-D homology models of both the human and mouse orthologs of OCT3, conducted docking studies and HINT analysis, and identified critical amino acid residues interacting with 2-aminodihydroquinazoline analogs at hOCT3 and mOCT3. Retention of antidepressant-like activity in the mouse and potential locomotor stimulant effects for TST-active doses were thoroughly investigated. We have successfully investigated initial SAR of 2-aminodihydroquinazolines at hOCT3 and generated the first 3-D homology models of hOCT3 and mOCT3. Highly potent and selective compounds could potentially be developed as radioligands to probe the binding site of OCT3 and as a mechanistically novel class of antidepressants.
author Iyer, Kavita A
author_facet Iyer, Kavita A
author_sort Iyer, Kavita A
title EXPLORING THE CONCEPT OF HUMAN OCT3 INHIBITORS AS A NOVEL CLASS OF ANTIDEPRESSANTS
title_short EXPLORING THE CONCEPT OF HUMAN OCT3 INHIBITORS AS A NOVEL CLASS OF ANTIDEPRESSANTS
title_full EXPLORING THE CONCEPT OF HUMAN OCT3 INHIBITORS AS A NOVEL CLASS OF ANTIDEPRESSANTS
title_fullStr EXPLORING THE CONCEPT OF HUMAN OCT3 INHIBITORS AS A NOVEL CLASS OF ANTIDEPRESSANTS
title_full_unstemmed EXPLORING THE CONCEPT OF HUMAN OCT3 INHIBITORS AS A NOVEL CLASS OF ANTIDEPRESSANTS
title_sort exploring the concept of human oct3 inhibitors as a novel class of antidepressants
publisher VCU Scholars Compass
publishDate 2016
url http://scholarscompass.vcu.edu/etd/4607
http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=5674&context=etd
work_keys_str_mv AT iyerkavitaa exploringtheconceptofhumanoct3inhibitorsasanovelclassofantidepressants
_version_ 1718429526632955904